NTLA - Intellia Therapeutics Inc Stock Price, Fair Value and News

19.79USD-1.38 (-6.52%)Delayed as of 25 Apr 2024, 10:06 am ET

Market Summary

USD19.79-1.38

Delayedas of 25 Apr 2024, 10:06 am

-6.52%

NTLA Stock Price

View Fullscreen

NTLA RSI Chart

NTLA Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-4.23

Price/Sales (Trailing)

56.09

EV/EBITDA

-40.19

Price/Free Cashflow

-4.99

NTLA Price/Sales (Trailing)

NTLA Profitability

EBT Margin

-186.20%

Return on Equity

-45.82%

Return on Assets

-36.99%

Free Cashflow Yield

-20.06%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

36.3M

Rev. Growth (Yr)

-9.6%

Rev. Growth (Qtr)

-11.78%

NTLA Earnings

Earnings (TTM)

-481.2M

Earnings Growth (Yr)

-16.54%

Earnings Growth (Qtr)

-8.13%

Breaking Down NTLA Revenue

52 Week Range

19.7947.48

(Low)(High)

Last 7 days

-1.5%

Last 30 days

-21.1%

Last 90 days

-15.6%

Trailing 12 Months

-41.6%

How does NTLA drawdown profile look like?

NTLA Financial Health

Current Ratio

8.67

NTLA Investor Care

Shares Dilution (1Y)

9.19%

Diluted EPS (TTM)

-5.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	53.5M	53.0M	51.8M	36.3M
2022	37.9M	45.3M	51.4M	52.1M
2021	51.5M	41.8M	26.8M	33.1M
2020	45.6M	50.7M	62.3M	58.0M
2019	33.4M	36.8M	40.0M	43.1M
2018	27.4M	29.1M	29.2M	30.4M
2017	20.9M	22.6M	25.1M	26.1M
2016	6.5M	9.4M	12.5M	16.5M
2015	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Intellia Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	clark eliana	sold	-19,958	32.99	-605	evp, chief technical officer
Mar 04, 2024	basta james	sold	-75,778	32.99	-2,297	evp, general counsel
Mar 01, 2024	goddard glenn	acquired	-	-	28,628	evp, chief financial officer
Mar 01, 2024	hicks derek	acquired	-	-	29,393	evp, chief business officer
Mar 01, 2024	basta james	acquired	-	-	32,394	evp, general counsel
Mar 01, 2024	clark eliana	acquired	-	-	31,230	evp, chief technical officer
Mar 01, 2024	sepp-lorenzino laura	acquired	-	-	37,966	evp, chief scientific officer
Mar 01, 2024	leonard john m	acquired	-	-	113,586	president and ceo
Mar 01, 2024	lebwohl david	acquired	-	-	38,701	evp, chief medical officer
Jan 08, 2024	sepp-lorenzino laura	sold	-65,681	28.8711	-2,275	evp, chief scientific officer

Which funds bought or sold NTLA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-64.95	-179,000	83,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	reduced	-5.97	-60.00	1,733	-%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-5.06	-690	4,127	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-52,541	1,417,660	0.01%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	3.64	-71,692	1,032,810	-%
Apr 22, 2024	Relyea Zuckerberg Hanson LLC	reduced	-16.96	-101,067	301,950	0.05%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	15.07	156,734	4,253,710	-%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	reduced	-2.28	-12,546,100	93,515,200	0.06%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-6,000	-	-%
Apr 19, 2024	AZZAD ASSET MANAGEMENT INC /ADV	added	2.08	-20,025	233,729	0.03%

Are Funds Buying or Selling NTLA?

Are funds buying NTLA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NTLA

No. of Funds

Unveiling Intellia Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.32%	8,347,449	SC 13G/A
Jan 29, 2024	ark investment management llc	12.74%	11,412,449	SC 13G/A
Jan 24, 2024	state street corp	5.29%	4,735,861	SC 13G/A
Jan 08, 2024	blackrock inc.	10.1%	9,010,695	SC 13G/A
Feb 10, 2023	ark investment management llc	11.20%	9,420,782	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.28%	7,810,226	SC 13G/A
Jan 25, 2023	blackrock inc.	8.7%	7,254,921	SC 13G
Feb 14, 2022	nikko asset management americas, inc.	3.70%	2,753,903	SC 13G/A
Feb 11, 2022	regeneron pharmaceuticals, inc.	4.98%	3,702,995	SC 13G/A

Recent SEC filings of Intellia Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	3	Insider Trading
Apr 16, 2024	PRE 14A	PRE 14A
Apr 15, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Intellia Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Intellia Therapeutics Inc News

Latest updates

Intellia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	11,992,000	13,594,000	12,606,000	13,573,000	13,266,000	14,030,000	11,252,000	12,854,000	7,204,000	6,550,000	6,445,000	6,595,000	22,220,000	16,263,000	12,916,000	10,936,000	10,616,000	11,118,000	10,433,000	7,880,000
Costs and Expenses	-3.6%	137,975,000	143,099,000	145,928,000	124,564,000	123,660,000	118,796,000	112,331,000	155,498,000	93,269,000	79,197,000	75,567,000	52,870,000	48,994,000	50,322,000	49,297,000	45,964,000	40,707,000	35,944,000	38,578,000	34,242,000	28,626,000
S&GA Expenses	-1.4%	28,994,000	29,403,000	30,652,000	27,448,000	23,626,000	22,145,000	22,132,000	22,403,000	22,108,000	18,711,000	16,683,000	13,594,000	10,763,000	10,566,000	11,526,000	11,314,000	8,976,000	8,431,000	13,118,000	10,533,000	8,708,000
R&D Expenses	-4.1%	108,981,000	113,696,000	115,276,000	97,116,000	100,034,000	96,651,000	90,199,000	133,095,000	71,161,000	60,486,000	58,884,000	39,276,000	38,231,000	39,756,000	37,771,000	34,650,000	31,731,000	27,513,000	25,460,000	23,709,000	19,918,000
EBITDA Margin	-41.6%	-1.61	-1.14	-1.12	-1.12	-1.15	-1.17	-1.33	-1.60	-1.83	-2.27	-1.46	-1.19	-	-	-	-	-	-	-	-	-
EBT Margin	-42.7%	-1.86	-1.30	-1.27	-1.26	-1.30	-1.31	-1.49	-1.78	-2.04	-2.52	-1.62	-1.31	-	-	-	-	-	-	-	-	-
Net Income	-8.1%	-132,161,000	-122,224,000	-123,681,000	-103,126,000	-113,407,000	-113,229,000	-100,678,000	-146,872,000	-81,237,000	-71,644,000	-68,806,000	-46,205,000	-42,192,000	-27,840,000	-32,393,000	-31,806,000	-28,276,000	-23,634,000	-25,683,000	-21,940,000	-19,066,000
Net Income Margin	-48.5%	-13.27	-8.93	-8.55	-8.05	-9.10	-8.60	-8.83	-9.73	-8.10	-8.54	-4.43	-2.88	-	-	-	-	-	-	-	-	-
Free Cashflow	10.5%	-94,574,000	-105,713,000	-94,624,000	-113,160,000	-93,781,000	-82,763,000	-89,071,000	-81,230,000	-57,519,000	-69,560,000	-55,919,000	-54,788,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	4.6%	1,301	1,243	1,323	1,418	1,520	1,084	1,110	1,203	1,294	1,335	672	717	676	459	491	315	334	347	352	344	347
Current Assets	11.7%	998	893	940	964	1,217	859	895	875	769	815	549	601	617	416	446	270	289	296	307	304	325
Cash Equivalents	34.9%	227	168	172	294	524	141	148	133	123	335	130	142	160	180	362	81.00	57.00	38.00	49.00	47.00	59.00
Net PPE	-3.1%	33.00	34.00	33.00	32.00	28.00	27.00	26.00	24.00	21.00	20.00	19.00	16.00	16.00	16.00	16.00	17.00	18.00	17.00	17.00	17.00	17.00
Liabilities	21.8%	251	206	-	-	285	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	25.3%	115	92.00	100	103	127	131	124	126	126	98.00	74.00	61.00	64.00	56.00	59.00	35.00	36.00	38.00	38.00	39.00	41.00
Shareholder's Equity	1.2%	1,050	1,037	1,105	1,191	1,236	825	881	954	1,040	1,107	495	546	527	330	352	248	270	276	277	264	278
Retained Earnings	-8.7%	-1,658	-1,526	-1,403	-1,280	-1,177	-1,063	-950	-849	-703	-621	-550	-481	-435	-392	-365	-332	-300	-272	-248	-223	-201
Additional Paid-In Capital	5.6%	2,711	2,567	2,513	2,474	2,420	1,898	1,841	1,812	1,746	1,729	1,045	1,027	962	723	717	580	570	548	526	488	479
Shares Outstanding	4.4%	93.00	89.00	88.00	88.00	87.00	76.00	75.00	75.00	71.00	70.00	68.00	67.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,565	-	-	-	3,889	-	-	-	10,926	-	-	-	1,183	-	-	-	741	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	8.2%	-93,054	-101,381	-90,323	-109,328	-89,869	-78,526	-85,091	-79,801	-54,651	-65,022	-52,981	-52,376	-40,226	-28,558	57,417	-38,545	-28,662	-25,448	-27,677	-21,453	-8,538
Share Based Compensation	-0.9%	35,043	35,352	36,400	27,255	24,626	25,215	23,068	18,491	14,561	15,410	10,614	6,424	5,582	5,400	4,764	4,157	3,016	3,079	4,404	4,592	3,582
Cashflow From Investing	-42.2%	45,939	79,500	-34,538	-122,248	-30,152	47,643	95,345	47,473	-159,115	-399,381	33,260	-25,542	-210,918	-153,980	92,963	57,448	27,884	-31,652	23,249	5,695	-256,016
Cashflow From Financing	457.4%	106,484	19,102	2,516	2,221	505,763	23,977	5,895	47,320	2,280	668,680	7,133	58,595	234,093	597	132,225	4,864	19,564	46,400	6,471	3,999	30,162

NTLA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 36,275	$ 52,121	$ 33,053
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 435,069	$ 419,979	$ 229,807
General and administrative	116,497	90,306	71,096
Total operating expenses	551,566	510,285	300,903
Operating loss	(515,291)	(458,164)	(267,850)
Other income (expense), net:
Interest income	49,832	8,542	1,283
Loss from equity method investments	(15,633)	(11,079)	(1,325)
Change in fair value of contingent consideration	(100)	(13,485)	0
Total other income (expense), net	34,099	(16,022)	(42)
Net loss	$ (481,192)	$ (474,186)	$ (267,892)
Net Loss Per Share, Basic	$ (5.42)	$ (6.16)	$ (3.78)
Net Loss Per Share, Diluted	$ (5.42)	$ (6.16)	$ (3.78)
Weighted average shares outstanding, basic	88,770	76,972	70,894
Weighted average shares outstanding, diluted	88,770	76,972	70,894
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	$ 3,635	$ (1,637)	$ (2,126)
Other comprehensive gain (loss) from equity method investment	1,568	(3,192)	(507)
Comprehensive loss	$ (475,989)	$ (479,015)	$ (270,525)

NTLA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 226,748	$ 523,506
Marketable securities	685,475	669,116
Accounts receivable ($0.2 million and $0.3 million, respectively,from related party)	36,456	3,768
Prepaid expenses and other current assets	49,651	20,407
Total current assets	998,330	1,216,797
Marketable securities - noncurrent	99,864	69,338
Property and equipment, net	32,760	27,921
Operating lease right-of-use assets	115,375	133,076
Equity method investment	11,765	32,455
Investments and other assets	42,883	40,527
Total Assets	1,300,977	1,520,114
Current Liabilities:
Accounts payable	7,452	5,154
Accrued expenses ($1.0 million and $1.6 million, respectively, from related party)	67,017	60,876
Current portion of operating lease liability	18,599	16,685
Current portion of deferred revenue ($0 and $19.9 million, respectively,from related party)	22,140	43,839
Total current liabilities	115,208	126,554
Deferred revenue, net of current portion	38,853	19,932
Long-term operating lease liability	96,747	114,018
Contingent consideration liability	0	24,026
Total liabilities	250,808	284,530
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively;92,997,158 and 87,103,007 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	9	9
Additional paid-in capital	2,710,797	2,420,223
Accumulated other comprehensive loss	(2,258)	(7,461)
Accumulated deficit	(1,658,379)	(1,177,187)
Total stockholders’ equity	1,050,169	1,235,584
Total Liabilities and Stockholders’ Equity	$ 1,300,977	$ 1,520,114

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. John M. Leonard M.D.
WEBSITE	intelliatx.com
INDUSTRY	Biotechnology
EMPLOYEES	598

Intellia Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Intellia Therapeutics Inc? What does NTLA stand for in stocks?

NTLA is the stock ticker symbol of Intellia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intellia Therapeutics Inc (NTLA)?

As of Wed Apr 24 2024, market cap of Intellia Therapeutics Inc is 2.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers. The fair value of Intellia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intellia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NTLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intellia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NTLA is over valued or under valued. Whether Intellia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Intellia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTLA.

What is Intellia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, NTLA's PE ratio (Price to Earnings) is -4.23 and Price to Sales (PS) ratio is 56.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTLA PE ratio will change depending on the future growth rate expectations of investors.